BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 18049028)

  • 1. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
    Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness.
    Yasmin ; McEniery CM; Wallace S; Dakham Z; Pulsalkar P; Maki-Petaja K; Ashby MJ; Cockcroft JR; Wilkinson IB
    Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):372. PubMed ID: 15556929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The changes and impact factors of carotid-femoral and carotid-radial pulse wave velocity in patients with essential hypertension].
    Hua Q; Tan J; Liu DX; Wen J; Xing XR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Dec; 33(12):1088-91. PubMed ID: 16563276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
    Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
    Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of perindopril on elastic and structural properties of large arteries in essential hypertension.
    Lacourcière Y; Béliveau R; Conter HS; Burgess ED; Lepage S; Pesant Y; Spence JD; Asmar R; Carrière S; Plante GE;
    Can J Cardiol; 2004 Jun; 20(8):795-9. PubMed ID: 15229761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
    Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects.
    McNulty M; Mahmud A; Spiers P; Feely J
    J Hum Hypertens; 2006 Nov; 20(11):867-73. PubMed ID: 16598292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension.
    Zhou S; Feely J; Spiers JP; Mahmud A
    J Hum Hypertens; 2007 Nov; 21(11):861-7. PubMed ID: 17581602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collagen metabolism in extracellular matrix may be involved in arterial stiffness in older hypertensive patients with left ventricular hypertrophy.
    Ishikawa J; Kario K; Matsui Y; Shibasaki S; Morinari M; Kaneda R; Hoshide S; Eguchi K; Hojo Y; Shimada K
    Hypertens Res; 2005 Dec; 28(12):995-1001. PubMed ID: 16671339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
    Głowińska-Olszewska B; Urban M
    Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B; Głowińska B; Urban M; Peczyńska J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative association between serum levels of matrix metalloproteinases-2 and -9 and aortic stiffness in healthy adults.
    Vlachopoulos C; Aznaouridis K; Dima I; Ioakeimidis N; Vasiliadou C; Zervoudaki A; Gialernios T; Stefanadis C
    Int J Cardiol; 2007 Nov; 122(3):232-8. PubMed ID: 17289174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
    Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals.
    Yasmin ; McEniery CM; O'Shaughnessy KM; Harnett P; Arshad A; Wallace S; Maki-Petaja K; McDonnell B; Ashby MJ; Brown J; Cockcroft JR; Wilkinson IB
    Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1799-805. PubMed ID: 16709939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.